Rocket Pharmaceuticals (RCKT)

• Market cap: $348M
• 1 day: -2.74%
• 5 days: -7.8%
• 1 month: -3.33%
• 3 months: -9.38%
• 6 months: -12.12%
• Year to date: -7.8%
• 1 year: -0.62%
• 5 years: -91.82%
• 10 years: -91.38%
• Sector: Healthcare
• Industry: Biotechnology

About: Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.

Employees: 202